Pharma Focus Asia

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Siemens and Akesobio Join Forces to Drive Forward the Development of Bio-pharma In- dustry in China towards an Intelligent Era

Thursday, February 24, 2022

Siemens signed a commercial contract and a technical agreement with Akeso Sano Pharma Co Ltd one of the whollyowned subsidiaries of Akesobio for indepth cooperation in the field of automation digitalization and intelligence The cooperation aims to he...

Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™

Monday, February 28, 2022

Acerus Pharmaceuticals Corporation today announced that it has entered into a definitive agreement the Definitive Agreement to indirectly acquire Serenity LLC Serenity and the global rights to its Noctiva brand in a combined cash and stock transactio...

Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan

Monday, February 28, 2022

Crinetics Pharmaceuticals Inc a clinical stage pharmaceutical company focused on the discovery development and commercialization of novel therapeutics for rare endocrine diseases and endocrinerelated tumors and Sanwa Kagaku Kenkyusho Co Ltd Sanwa an...

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Monday, February 28, 2022

Design Therapeutics Inc a biotechnology company developing treatments for degenerative genetic disorders today announced that its Investigational New Drug Application IND for its lead candidate DT for the treatment of Friedreich ataxia FA was cleared...

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment

Monday, February 28, 2022

Bristol Myers Squibb announced that the US Food and Drug Administration FDA has accepted the supplemental Biologics License Application sBLA for Opdivo nivolumab plus chemotherapy for the neoadjuvant treatment of patients with resectable nonsmall cel...

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis

Monday, February 28, 2022

Lynk Pharmaceuticals Co Ltd hereinafter referred to as Lynk Pharmaceuticals an innovative clinical stage company announced that it had dosed the first patient with LNK in its Phase II clinical trial on subjects with atopic dermatitis AD LNK is a sele...

Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer

Monday, February 28, 2022

Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes highquality medicines for the treatment of oncology metabolic autoimmune and other major diseases together with AnHeart Therapeutics AnHeart a...

Better Therapeutics Announces New CMS HCPCS Code for Prescription Digital Behavioral Therapies (PDTs)

Monday, February 28, 2022

Better Therapeutics Inc a prescription digital therapeutics PDT company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases announces a new code from the Center for Medicare and Medicaid Services CMS that pa...

Arla Food Ingredients and Zerion Pharma complete long-term supply agreement for beta-lactoglobulin (Lacprodan® BLG-100)

Thursday, February 24, 2022

Zerion Pharma AS announces today that it has executed a longterm agreement with Arla Food Ingredients covering the supply of its Lacprodan BLG for use as a pharmaceutical excipient in connection with ZERIONs patented Dispersome technology Arla Foods...

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Thursday, February 24, 2022

Cyclerion Therapeutics Inc and Ariana Pharma today announced an artificial intelligencedriven precision medicine collaboration This collaboration is expected to identify biomarkers of response to refine patient selection to guide and accelerate the c...